☰

Lazar N. Vujanovic, Ph.D. - Publications

Affiliations: 
2006 University of Pittsburgh, Pittsburgh, PA, United States 
Area:
Immunology, Cell Biology, Molecular Biology
Tree Info Similar researchers PubMed Report error

31 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2023 Luke J, Dadey R, Augustin R, Newman S, Singh K, Doerfler R, Behr S, Lee P, Isett B, Deitrick C, Li A, Joy M, Reeder C, Smith K, Urban J, et al. Tumor cell p38 inhibition to overcome immunotherapy resistance. Research Square. PMID 37645831 DOI: 10.21203/rs.3.rs-3183496/v1  0.452
2022 Chen X, Chen L, Kürten CHL, Jabbari F, Vujanovic L, Ding Y, Lu B, Lu K, Kulkarni A, Tabib T, Lafyatis R, Cooper GF, Ferris R, Lu X. An individualized causal framework for learning intercellular communication networks that define microenvironments of individual tumors. Plos Computational Biology. 18: e1010761. PMID 36548438 DOI: 10.1371/journal.pcbi.1010761  0.323
2022 Janjic BM, Kulkarni A, Ferris RL, Vujanovic L, Vujanovic NL. Human B Cells Mediate Innate Anti-Cancer Cytotoxicity Through Concurrent Engagement of Multiple TNF Superfamily Ligands. Frontiers in Immunology. 13: 837842. PMID 35392082 DOI: 10.3389/fimmu.2022.837842  0.404
2021 Kürten CHL, Kulkarni A, Cillo AR, Santos PM, Roble AK, Onkar S, Reeder C, Lang S, Chen X, Duvvuri U, Kim S, Liu A, Tabib T, Lafyatis R, Feng J, ... ... Vujanovic L, et al. Investigating immune and non-immune cell interactions in head and neck tumors by single-cell RNA sequencing. Nature Communications. 12: 7338. PMID 34921143 DOI: 10.1038/s41467-021-27619-4  0.407
2021 Banerjee H, Nieves-Rosado H, Kulkarni A, Murter B, McGrath KV, Chandran UR, Chang A, Szymczak-Workman AL, Vujanovic L, Delgoffe GM, Ferris RL, Kane LP. Expression of Tim-3 drives phenotypic and functional changes in Treg cells in secondary lymphoid organs and the tumor microenvironment. Cell Reports. 36: 109699. PMID 34525351 DOI: 10.1016/j.celrep.2021.109699  0.509
2020 Santos PM, Adamik J, Howes TR, Du S, Vujanovic L, Warren S, Gambotto A, Kirkwood JM, Butterfield LH. Impact of checkpoint blockade on cancer vaccine-activated CD8+ T cell responses. The Journal of Experimental Medicine. 217. PMID 32369107 DOI: 10.1084/Jem.20191369  0.511
2020 Gorry M, Yoneyama T, Vujanovic L, Moss ML, Garlin MA, Miller MA, Herman J, Stabile LP, Vujanovic NL. Development of flow cytometry assays for measuring cell-membrane enzyme activity on individual cells. Journal of Cancer. 11: 702-715. PMID 31942194 DOI: 10.7150/Jca.30813  0.384
2020 Kürten C, Kulkarni A, Chen X, Vujanovic L, Cillo A, Lu X, Ferris RL. Abstract PR03: The tumor microenvironment (TME) in head and neck squamous cell carcinoma (HNSCC): Investigating new aspects of known cell types using single-cell RNA sequencing Clinical Cancer Research. 26. DOI: 10.1158/1557-3265.Aacrahns19-Pr03  0.539
2019 Butterfield LH, Vujanovic L, Santos PM, Maurer DM, Gambotto A, Lohr J, Li C, Waldman J, Chandran U, Lin Y, Lin H, Tawbi HA, Tarhini AA, Kirkwood JM. Multiple antigen-engineered DC vaccines with or without IFNα to promote antitumor immunity in melanoma. Journal For Immunotherapy of Cancer. 7: 113. PMID 31014399 DOI: 10.1186/S40425-019-0552-X  0.424
2019 Maurer DM, Butterfield LH, Vujanovic L. Melanoma vaccines: clinical status and immune endpoints. Melanoma Research. 29: 109-118. PMID 30802228 DOI: 10.1097/Cmr.0000000000000535  0.473
2019 Vujanovic L, Chuckran C, Lin Y, Ding F, Sander CA, Santos PM, Lohr J, Mashadi-Hossein A, Warren S, White A, Huang A, Kirkwood JM, Butterfield LH. CD56 CD16 Natural Killer Cell Profiling in Melanoma Patients Receiving a Cancer Vaccine and Interferon-α. Frontiers in Immunology. 10: 14. PMID 30761123 DOI: 10.3389/Fimmu.2019.00014  0.561
2018 Yoneyama T, Gorry M, Sobo-Vujanovic A, Lin Y, Vujanovic L, Gaither-Davis A, Moss ML, Miller MA, Griffith LG, Lauffenburger DA, Stabile LP, Herman J, Vujanovic NL. ADAM10 Sheddase Activity is a Potential Lung-Cancer Biomarker. Journal of Cancer. 9: 2559-2570. PMID 30026855 DOI: 10.7150/Jca.24601  0.392
2017 Vujanovic L, Stahl EC, Pardee AD, Geller DA, Tsung A, Watkins SC, Gibson GA, Storkus WJ, Butterfield LH. Tumor-derived α-fetoprotein directly drives human natural killer cell activation and subsequent cell death. Cancer Immunology Research. PMID 28468916 DOI: 10.1158/2326-6066.Cir-16-0216  0.708
2016 Sobo-Vujanovic A, Vujanovic L, DeLeo AB, Concha-Benavente F, Ferris RL, Lin Y, Vujanovic NL. Inhibition of soluble tumor necrosis factor prevents chemically-induced carcinogenesis in mice. Cancer Immunology Research. PMID 26896171 DOI: 10.1158/2326-6066.Cir-15-0104  0.347
2015 Pardee AD, Yano H, Weinstein AM, Ponce AA, Ethridge AD, Normolle DP, Vujanovic L, Mizejewski GJ, Watkins SC, Butterfield LH. Route of antigen delivery impacts the immunostimulatory activity of dendritic cell-based vaccines for hepatocellular carcinoma. Journal For Immunotherapy of Cancer. 3: 32. PMID 26199728 DOI: 10.1186/S40425-015-0077-X  0.722
2015 Vujanovic L, Stahl E, Pardee A, Watkins S, Gibson G, Butterfield LH. Tumor-derived alpha fetoprotein directly impacts human natural killer cell activity and viability Journal For Immunotherapy of Cancer. 3. DOI: 10.1186/2051-1426-3-S2-P289  0.742
2014 Vujanovic L, Shi J, Kirkwood JM, Storkus WJ, Butterfield LH. Molecular mimicry of MAGE-A6 and Mycoplasma penetrans HF-2 epitopes in the induction of antitumor CD8(+) T-cell responses. Oncoimmunology. 3: e954501. PMID 25960935 DOI: 10.4161/21624011.2014.954501  0.654
2014 Vujanovic LN, Stahl E, Butterfield LH. Alpha fetoprotein directly induces a unique pro-inflammatory, IL-2 hyperresponsive phenotype in human natural killer cells Journal For Immunotherapy of Cancer. 2: 178. DOI: 10.1186/2051-1426-2-S3-P178  0.615
2013 Naveh HP, Vujanovic L, Butterfield LH. Cellular immunity induced by a recombinant adenovirus- human dendritic cell vaccine for melanoma Journal For Immunotherapy of Cancer. 1: 19-19. PMID 24829755 DOI: 10.1186/2051-1426-1-19  0.53
2013 Baskic D, Vujanovic L, Arsenijevic N, Whiteside TL, Myers EN, Vujanovic NL. Suppression of natural killer-cell and dendritic-cell apoptotic tumoricidal activity in patients with head and neck cancer Head and Neck-Journal For the Sciences and Specialties of the Head and Neck. 35: 388-398. PMID 22488918 DOI: 10.1002/Hed.22968  0.59
2012 Vujanovic L, Ballard W, Thorne SH, Vujanovic NL, Butterfield LH. Adenovirus-engineered human dendritic cells induce natural killer cell chemotaxis via CXCL8/IL-8 and CXCL10/IP-10. Oncoimmunology. 1: 448-457. PMID 22754763 DOI: 10.4161/Onci.19788  0.565
2012 Blalock LT, Landsberg J, Messmer M, Shi J, Pardee AD, Haskell R, Vujanovic L, Kirkwood JM, Butterfield LH. Human dendritic cells adenovirally-engineered to express three defined tumor antigens promote broad adaptive and innate immunity. Oncoimmunology. 1: 287-357. PMID 22737604 DOI: 10.4161/Onci.18628  0.736
2011 Bray SM, Vujanovic L, Butterfield LH. Dendritic cell-based vaccines positively impact natural killer and regulatory T cells in hepatocellular carcinoma patients. Clinical & Developmental Immunology. 2011: 249281. PMID 21969837 DOI: 10.1155/2011/249281  0.649
2011 Butterfield LH, Vujanovic L. New approaches to the development of adenoviral dendritic cell vaccines in melanoma. Current Opinion in Investigational Drugs (London, England : 2000). 11: 1399-408. PMID 21154122  0.393
2010 Vujanovic L, Szymkowski DE, Alber S, Watkins SC, Vujanovic NL, Butterfield LH. Virally infected and matured human dendritic cells activate natural killer cells via cooperative activity of plasma membrane-bound TNF and IL-15. Blood. 116: 575-583. PMID 20430958 DOI: 10.1182/Blood-2009-08-240325  0.584
2009 Ge L, Baskic D, Basse P, Vujanovic L, Unlu S, Yoneyama T, Vujanovic A, Han J, Bankovic D, Szczepanski MJ, Hunt JL, Herberman RB, Gollin SM, Ferris RL, Whiteside TL, et al. Sheddase activity of tumor necrosis factor-alpha converting enzyme is increased and prognostically valuable in head and neck cancer. Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association For Cancer Research, Cosponsored by the American Society of Preventive Oncology. 18: 2913-22. PMID 19843672 DOI: 10.1158/1055-9965.Epi-08-0898  0.418
2009 Vujanovic L, Whiteside TL, Potter DM, Chu J, Ferrone S, Butterfield LH. Regulation of antigen presentation machinery in human dendritic cells by recombinant adenovirus. Cancer Immunology, Immunotherapy : Cii. 58: 121-33. PMID 18488218 DOI: 10.1007/S00262-008-0533-2  0.585
2008 Butterfield LH, Comin-Anduix B, Vujanovic L, Lee Y, Dissette VB, Yang JQ, Vu HT, Seja E, Oseguera DK, Potter DM, Glaspy JA, Economou JS, Ribas A. Adenovirus MART-1-engineered autologous dendritic cell vaccine for metastatic melanoma. Journal of Immunotherapy (Hagerstown, Md. : 1997). 31: 294-309. PMID 18317358 DOI: 10.1097/Cji.0B013E31816A8910  0.637
2007 Vujanovic L, Mandic M, Olson WC, Kirkwood J, Storkus WJ. A mycoplasma peptide elicits heteroclitic CD4+ T cell responses against tumor antigen MAGE-A6 Clinical Cancer Research. 13: 6796-6806. PMID 18006782 DOI: 10.1158/1078-0432.Ccr-07-1909  0.644
2007 Vujanovic L, Butterfield LH. Melanoma cancer vaccines and anti‐tumor T cell responses Journal of Cellular Biochemistry. 102: 301-310. PMID 17647270 DOI: 10.1002/Jcb.21473  0.511
2006 Vujanovic L, Ranieri E, Gambotto A, Olson WC, Kirkwood JM, Storkus WJ. IL-12p70 and IL-18 gene-modified dendritic cells loaded with tumor antigen-derived peptides or recombinant protein effectively stimulate specific Type-1 CD4+ T-cell responses from normal donors and melanoma patients in vitro Cancer Gene Therapy. 13: 798-805. PMID 16645618 DOI: 10.1038/Sj.Cgt.7700964  0.668
Show low-probability matches.